Trillium Therapeutics’ (TR) Market Perform Rating Reiterated at Leerink Swann

Trillium Therapeutics (TSE:TR) (NASDAQ:TRIL)‘s stock had its “market perform” rating restated by equities researchers at Leerink Swann in a research report issued to clients and investors on Friday.

Trillium Therapeutics stock opened at C$30.20 on Friday. Trillium Therapeutics has a one year low of C$28.50 and a one year high of C$39.45.

How to Become a New Pot Stock Millionaire

Trillium Therapeutics (TSE:TR) (NASDAQ:TRIL) last released its quarterly earnings data on Friday, March 9th. The company reported C($0.91) EPS for the quarter, beating the consensus estimate of C($1.06) by C$0.15.

TRADEMARK VIOLATION WARNING: “Trillium Therapeutics’ (TR) Market Perform Rating Reiterated at Leerink Swann” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/17/trillium-therapeutics-tr-market-perform-rating-reiterated-at-leerink-swann.html.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1).

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply